Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

Today, Benzinga 's options scanner spotted 10 uncommon options trades for Abbott Laboratories. This isn't normal. The overall ...

neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott ...

Abbott received a breakthrough device designation ... According to Dr Brian Kopell, director of the Center for Neuromodulation at Mount Sinai West and principal investigator of the trial, there ...

Abbott Neuromodulation's Jenn Wong discusses the TRANSCEND trial for depression, imaging tech advancing DBS and other ...

In most cases, Abbott is one of three or four competitors that dominate the market, including nutrition, cardiac rhythm management devices, surgical heart valves, continuous glucose monitors, coronary ...

neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott ...

Experts estimate that treatment-resistant depression (TRD) impacts about 2.8 million Americans annually, and a groundbreaking ...

Brian Kopell, M.D. Director of the Center for Neuromodulation/ Movement Disorders ... Healthcare company Abbott announced the initiation of its Abbott TRANSCEND study that evaluates the use ...

The global neuromodulation device market is one of the fastest growing ... The report indicates that Medtronic has the largest market share, followed by Boston Scientific and Abbott. Cortigent’s ...